The new in anticoagulation: factor XI inhibitors

Area of Science:

• Coagulation and Haemostasis
• Pharmacological Inhibition
• Thrombosis and Anticoagulation

Background:

• Haemostasis and thrombosis are intrinsically linked, posing a challenge for anticoagulant therapies that increase bleeding risk.
• The contact pathway, specifically factor XI (FXI), is implicated in thrombosis with potential for targeted inhibition.
• Current anticoagulants carry inherent bleeding risks, necessitating exploration of alternative strategies.

Purpose of the Study:

• To evaluate the potential of factor XI (FXI) inhibitors as a novel anticoagulant strategy.
• To assess the efficacy and safety of FXI inhibition in preventing thrombosis with minimal haemostatic interference.
• To explore the therapeutic utility of FXI inhibitors in various clinical settings and patient populations.

Main Methods:

• Review of epidemiological and experimental evidence on contact pathway and FXI inhibition.
• Analysis of ongoing and completed Phase 2 clinical trials for FXI inhibitors.
• Examination of FXI inhibitors' potential role alongside existing anticoagulant therapies.

Main Results:

• Phase 2 clinical trials in major orthopaedic surgery, end-stage renal disease, atrial fibrillation, and acute coronary syndrome show promising results for FXI inhibitors.
• FXI inhibition demonstrates potential for preventing thrombosis with reduced impact on haemostasis compared to traditional anticoagulants.
• Clinical research is progressing to Phase 3 trials based on positive Phase 2 outcomes.

Conclusions:

• Factor XI (FXI) inhibitors represent a promising therapeutic advancement in anticoagulation.
• FXI inhibitors may offer a safer alternative for patients at high risk of bleeding or those unresponsive to current treatments.
• While not replacing existing anticoagulants, FXI inhibitors could become a valuable addition to the therapeutic armamentarium for thrombosis prevention.